Substituted 4-amino-1-benzylpiperidine compounds

Details Substituted 4-amino-1-benzylpiperidine compounds Substituted 4-amino-1-benzylpiperidine compounds

2008-05-06

2008-05-06

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S208000

Reexamination Certificate

active

07368463

ABSTRACT:
This invention provides 4-amino-1-benzylpiperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome, asthma and chronic obstructive pulmonary disease, using such compounds.

REFERENCES:
patent: 3192206 (1965-06-01), Lunsford et al.
patent: 3192210 (1965-06-01), Lunsford et al.
patent: 3192221 (1965-06-01), Lunsford et al.
patent: 3984557 (1976-10-01), Welstead, Jr.
patent: 4002766 (1977-01-01), Welstead, Jr.
patent: 4594343 (1986-06-01), Shanklin, Jr. et al.
patent: 4810713 (1989-03-01), Yanni et al.
patent: 4950674 (1990-08-01), Yanni et al.
patent: 5026858 (1991-06-01), Vega-Noverola et al.
patent: 5028616 (1991-07-01), Desai et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 5096890 (1992-03-01), Cross et al.
patent: 5233053 (1993-08-01), Cross et al.
patent: 5281601 (1994-01-01), Cross et al.
patent: 5340831 (1994-08-01), Cross et al.
patent: 5344835 (1994-09-01), Alker et al.
patent: 5486527 (1996-01-01), Alker et al.
patent: 5607950 (1997-03-01), Alker et al.
patent: 5750540 (1998-05-01), Tsuchiya et al.
patent: 5932594 (1999-08-01), Cross et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6319920 (2001-11-01), Caroon et al.
patent: 6635764 (2003-10-01), Mammen et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 2002/0049195 (2002-04-01), Mammen et al.
patent: 2003/0055080 (2003-03-01), Fomer et al.
patent: 2004/0029919 (2004-02-01), Mammen et al.
patent: 2004/0054187 (2004-03-01), Mammen et al.
patent: 2004/0110229 (2004-06-01), Aggen et al.
patent: 2004/0116706 (2004-06-01), Mammen et al.
patent: 2004/0122014 (2004-06-01), Mammen et al.
patent: 628 885 (1982-03-01), None
patent: 0 178 946 (1986-04-01), None
patent: 0 178 947 (1986-04-01), None
patent: 0 235 463 (1987-09-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 823 423 (1998-02-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 0 999 205 (2000-05-01), None
patent: 1 020 449 (2000-07-01), None
patent: 1 507 462 (1978-04-01), None
patent: 1 575 310 (1980-09-01), None
patent: 1 593 851 (1981-07-01), None
patent: WO 91/09013 (1991-06-01), None
patent: WO 99/43657 (1999-09-01), None
patent: WO 99/64043 (1999-12-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO 02/051841 (2002-07-01), None
patent: WO 02/053564 (2002-07-01), None
patent: WO 03/048124 (2003-06-01), None
patent: WO 2004/041806 (2004-05-01), None
Bohme et al., 2002, J. Med. Chem., 45, 4800.
Bohme et al., 2002, J. Med. Chem., 45, 3094-3102.
Shanklin et al. “1-aminoalkyl . . . ” CA 105:114918 (1986).
Beringue et al. “Creutzfeldt-Jakob . . . ” CA 126:324757 (1997).
Tomlinson et al. “Neurotrophic factors . . . ” CA 127:174580 (1997).
Mammen et al. “Preparation of substituted 4-amino . . . ” CA 140:423591 (2004).
Mammen et al. “Preparation of substituted 4-aminl . . . ” CA 142:176696 (2005).
Broadley et al., “Muscarinic Receptor Agonists and Antagonists”, Molecules 2001, 6, pp. 142-193 (2001).
Eglen et al., “Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential”, DN&P, 10(8), pp. 462-469 (1997).
Eglen et al., “Selective modulation of muscarinic receptor subtypes: therapeutic potential”, Emerging Drugs:The Prospect for Improved Medicines/Annual Executive Briefing 1998; pp. 67-79 (1998).
Graul et al., “Darifenacin”, Drugs of the Future 1996, 21 (11); pp. 1105-1108 (1996).
Moragues et al., “Dopaminergic Activity in a Series of N-Substituted 2-Aminopyrimidines”, II Farmaco -Ed. Sc.- vol. 35 —Fasc. 11; pp. 951-964 (1980).
Shum et al., “The Design and Synthesis of Purine Inhibitors of CDK2.III”, Nucleosides, Nucleotides & Nucleic Acids, 20(4-7), pp. 1067-1078 (2001).
Taniguchi et al., “Agents for the Treatment of Overactive Detrusor. VI.1a)Synthesis and Pharmacological Properties of Acetamide Derivatives Bearing Cyclic Amines inN-Substituents”, Chem. Pharm. Bull., 42(1) pp. 74-84 (1994).
Zlotos et al., “Muscarinic receptor agonists and antagonists”, Exp. Opin. on Ther. Patents, 9(8), pp. 1029-1053 (1999).
Berge et al. “Pharmaceutical salts”, J. Pharm. Sciences, vol. 66, pp. 1-2 (1977).
CA 60:74793 (1964).
Pratesi et al. “Affinity and Intrinsic . . . ” CA 70:37081 (1969).
Laeckmann et al. “Synthesis and biological evaluation of aroylguanidines related to amiloride as inhibitors of the human platelet Na+ /H+ exchanger”, Bioorg. Med. Chem., vol. 10, pp. 1793-1804 (2002).
Wermuth “The practice of medicinal chemistry”, pp. 203-213 (1996).

Affiliated with

Also associated with

Rating

Substituted 4-amino-1-benzylpiperidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted 4-amino-1-benzylpiperidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-amino-1-benzylpiperidine compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2775227